



Crucell announces STAR™ Research License Agreement

Leiden, The Netherlands, January 31, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a non-exclusive STAR™ research license agreement for the production of monoclonal antibodies with Abbott Park, Illinois-based Abbott. Under the agreement, Abbott would evaluate Crucell's STAR(TM) technology for generating cell lines for manufacture of biopharmaceuticals. Financial details were not disclosed.

For further information please contact:

Crucell N.V.

Leonard Kruimer
Chief Financial Officer
Tel. +31-(0)71-524 8722
l.kruimer@crucell.com

Barbara Mulder
Tel: 31-(0) 71 524 8718
barbara.mulder@crucell.com